GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artgen Biotech PJSC (MIC:ABIO) » Definitions » Tax Rate %

Artgen Biotech PJSC (MIC:ABIO) Tax Rate % : 16.96% (As of Jun. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Artgen Biotech PJSC Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Artgen Biotech PJSC's Tax Expense for the six months ended in Jun. 2023 was ₽7 Mil. Artgen Biotech PJSC's Pre-Tax Income for the six months ended in Jun. 2023 was ₽43 Mil. Therefore, Artgen Biotech PJSC's Tax Rate % for the quarter that ended in Jun. 2023 was 16.96%.


Artgen Biotech PJSC Tax Rate % Historical Data

The historical data trend for Artgen Biotech PJSC's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artgen Biotech PJSC Tax Rate % Chart

Artgen Biotech PJSC Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Tax Rate %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 66.11 -9.75 -10.63 -13.88 21.26

Artgen Biotech PJSC Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.89 2.53 -1.69 -5,514.75 16.96

Artgen Biotech PJSC Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Artgen Biotech PJSC's Tax Rate % for the fiscal year that ended in Dec. 2022 is calculated as

Tax Rate %=Tax Expense (A: Dec. 2022 )/Pre-Tax Income (A: Dec. 2022 )
=6.23/29.305
=21.26 %

Artgen Biotech PJSC's Tax Rate % for the quarter that ended in Jun. 2023 is calculated as

Tax Rate %=Tax Expense (Q: Jun. 2023 )/Pre-Tax Income (Q: Jun. 2023 )
=7.369/43.437
=16.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Artgen Biotech PJSC Tax Rate % Related Terms

Thank you for viewing the detailed overview of Artgen Biotech PJSC's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.


Artgen Biotech PJSC Business Description

Traded in Other Exchanges
N/A
Address
Prospect of the 60th Anniversary, Moscow, RUS, 117036
Artgen Biotech PJSC formerly Human Stem Cells Institute PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.

Artgen Biotech PJSC Headlines

From GuruFocus

James Flynn Joins ARCA biopharma Board of Directors

By Value_Insider Value_Insider 12-19-2022

Jacob Ma-Weaver Joins ARCA biopharma Board of Directors

By GuruFocusNews GuruFocusNews 06-21-2022

ARCA biopharma Announces First Quarter 2023 Financial Results

By sperokesalga sperokesalga 04-24-2023

ARCA biopharma Announces Third Quarter 2022 Financial Results

By Value_Insider Value_Insider 10-28-2022